Waycaster C, Carter MJ, Gilligan AM, Mearns ES, Fife CE, Milne CT, et al.
Journal of comparative effectiveness research. Date of publication 2017 Oct 27;volume ():.
1. J Comp Eff Res. 2017 Oct 27. doi: 10.2217/cer-2017-0066. [Epub ahead of print]
Comparative cost and clinical effectiveness of clostridial collagenase ointment
for chronic dermal ulcers.
Waycaster C(1), Carter MJ(2), Gilligan AM(3), Mearns ES(4), Fife CE(5), Milne
CT(6).
Author information:
(1)Smith & Nephew, Fort Worth, TX 76109, USA.
(2)Strategic Solutions, Inc., Cody, WY 82414, USA.
(3)Truven Health Analytics, Houston, TX 77056, USA.
(4)Truven Health Analytics, an IBM Company, Cambridge, MA 02140, USA.
(5)Baylor College of Medicine, Houston, TX 77030, USA.
(6)Connecticut Clinical Nursing Associates, LLC, Bristol, CT 06011, USA.
Chronic dermal ulcers affect approximately 2.4-4.5 million people in the USA and
are associated with loss of function, decreased quality of life and significant
economic burden. Debridement is a critical component of wound care involving
removal of nonviable tissue from chronic wounds to stimulate the granulation and
epithelialization process. Clostridial collagenase ointment has been used as a
method of wound debridement for more than 50 years and is currently the only
enzymatic debriding ointment with US FDA approval. This review discusses the
results of recent real-world studies that build upon the evidence demonstrating
the clinical effectiveness, cost-effectiveness and safety of clostridial
collagenase ointment across wound types and care settings.
DOI: 10.2217/cer-2017-0066
PMID: 29076747
